524 related articles for article (PubMed ID: 19886148)
1. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?
Cannom RR; Kaiser AM; Ault GT; Beart RW; Etzioni DA
Am Surg; 2009 Oct; 75(10):976-80. PubMed ID: 19886148
[TBL] [Abstract][Full Text] [Related]
2. Trends in surgery for Crohn's disease in the era of infliximab.
Jones DW; Finlayson SR
Ann Surg; 2010 Aug; 252(2):307-12. PubMed ID: 20585239
[TBL] [Abstract][Full Text] [Related]
3. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
4. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
6. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
7. Trends in hospitalization rates for inflammatory bowel disease in the United States.
Bewtra M; Su C; Lewis JD
Clin Gastroenterol Hepatol; 2007 May; 5(5):597-601. PubMed ID: 17382602
[TBL] [Abstract][Full Text] [Related]
8. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume.
Ananthakrishnan AN; McGinley EL; Binion DG
Am J Gastroenterol; 2008 Nov; 103(11):2789-98. PubMed ID: 18684184
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization for inflammatory bowel disease in the United States between 1970 and 2004.
Sonnenberg A
J Clin Gastroenterol; 2009 Apr; 43(4):297-300. PubMed ID: 18936713
[TBL] [Abstract][Full Text] [Related]
10. Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review.
Waters H; Vanderpoel J; McKenzie S; Lunacsek O; Franklin M; Lennert B; Goff J; Augustyn DH
J Med Econ; 2011; 14(4):397-402. PubMed ID: 21595522
[TBL] [Abstract][Full Text] [Related]
11. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients.
Nguyen GC; Sam J
Am J Gastroenterol; 2008 Sep; 103(9):2272-80. PubMed ID: 18684186
[TBL] [Abstract][Full Text] [Related]
12. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease.
Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):789-94. PubMed ID: 17700265
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
14. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients.
Nguyen GC; Kaplan GG; Harris ML; Brant SR
Am J Gastroenterol; 2008 Jun; 103(6):1443-50. PubMed ID: 18513271
[TBL] [Abstract][Full Text] [Related]
15. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis.
Longobardi T; Jacobs P; Bernstein CN
Am J Gastroenterol; 2004 Apr; 99(4):650-5. PubMed ID: 15089897
[TBL] [Abstract][Full Text] [Related]
16. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
17. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.
Waters HC; Vanderpoel JE; Nejadnik B; McKenzie RS; Lunacsek OE; Lennert BJ; Goff J; Augustyn DH
J Med Econ; 2012; 15(1):45-52. PubMed ID: 22023068
[TBL] [Abstract][Full Text] [Related]
18. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.
Metge CJ; Blanchard JF; Peterson S; Bernstein CN
Am J Gastroenterol; 2001 Dec; 96(12):3348-55. PubMed ID: 11774948
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of chronic inflammatory bowel diseases].
Lémann M
Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
[TBL] [Abstract][Full Text] [Related]
20. The incidence of inflammatory bowel disease in the pediatric population of Southwestern Ontario.
Grieci T; Bütter A
J Pediatr Surg; 2009 May; 44(5):977-80. PubMed ID: 19433182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
